Urdiales J L, Morata P, Núñez De Castro I, Sánchez-Jiménez F
Laboratorio de Bioquimica y Biologiá Molecular. Facultad de Ciencias. Universidad de Málaga, Spain.
Cancer Lett. 1996 Apr 19;102(1-2):31-7. doi: 10.1016/0304-3835(96)04151-1.
The biological effects of dehydrodidemnin B(DDB), a novel depsipeptide isolated from Aplidium albicans, were studied on Ehrlich carcinoma growing in vivo and in primary cultures, and compared with those reported for Didemnin B (DB). Daily administration of DB or DDB (2.5 micrograms/mouse) almost duplicated the animal life-span and total number of tumour cells decreased by 70-90%. Results suggest a major effect of DDB when administered in the lag phase of growth. DDB behaved as a very potent inhibitor of protein synthesis; consequently, ornithine decarboxylase activity (ODC, EC 4.1.1.17) is drastically reduced by DDB-treatment.